Open AccessA Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease
Author(s) -
Zeyu Xie,
Jinjian Li,
Sensen Yang,
Weishang Deng,
Jisheng Chen
Publication year - 2022
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s375067
Subject(s) - medicine , lixisenatide , exenatide , dulaglutide , liraglutide , semaglutide , glucagon like peptide 1 receptor , pharmacology , agonist , type 2 diabetes , diabetes mellitus , endocrinology , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom